MedDataX Logo

Long Term Results and Complications After Epistaxis Treatment

NCT ID: NCT02127554

Last Updated: 2015-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

591 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to find the most agreeable and in the long term most efficient treatment for epistaxis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the general population epistaxis occurs quite frequently. Approximately 60% of persons will be affected once in their lifetime, and 6% thereof will seek medical advice. Thereby anterior and posterior epistaxis are discerned. Anterior epistaxis is usually located at the Locus Kisselbachii, while posterior bleeds are found further back in the nose. There, most bleeds will originate from the A. sphenopalatina or the A. ethmoidalis.

Different treatment modalities exist. Anterior epistaxis are usually easier to treat than posterior ones. The aim of this study is to find the most efficient treatment. This involves the assessment of long term results and potential sequelae. Existing data will be complemented with information about recurrences and complications. The question is: Which treatment method leads to the least numbers of recurrences in the long term with the fewest long term sequelae?

Secondly, the most agreeable, least painful treatment method is to be identified. Therefore we will send out questionnaires to patients that were treated between March 29, 2007 and April 1st, 2008 at the Zurich University Hospital.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nosebleed (Epistaxis) - Posterior or Anterior

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Electric coagulation

Patients with anterior epistaxis, treated with electric coagulation

No interventions assigned to this group

Chemical coagulation

Patients with anterior epistaxis, treated with chemical coagulation

No interventions assigned to this group

Outpatient tamponade

Patients with posterior epistaxis, treated with tamponade as an outpatient

No interventions assigned to this group

Inpatient tamponade

Patients with posterior epistaxis, treated with tamponade and kept in the hospital.

No interventions assigned to this group

Surgery

Patients with posterior epistaxis, treated with surgery as inpatients

No interventions assigned to this group

Foley balloon catheter

Patients with posterior epistaxis, treated as inpatients with Foley balloon catheter

No interventions assigned to this group

Combined treatment

Patients with posterior epistaxis, treated as inpatients with a combination of methods

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All patients treated during the study period with known address and who did not decease in the meantime.

Exclusion Criteria

Insufficiently filled out questionnaires; Obvious lack of ability to remember (as tested by control questions); Known mental disability
Minimum Eligible Age

14 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Soyka, Dr.med.

Role: PRINCIPAL_INVESTIGATOR

Zurich University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zurich University Hospital

Zurich, Canton of Zurich, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KEK-ZH-Nr: 2013-0519

Identifier Type: OTHER

Identifier Source: secondary_id

SM_21_01_2014

Identifier Type: -

Identifier Source: org_study_id